Glucagon‐like peptide‐1 receptor agonist‐based agents and weight loss composition: Filling the gaps
Diabetes Obesity and Metabolism,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 30, 2024
Abstract
Excess
adiposity
is
at
the
root
of
type
2
diabetes
(T2D).
Glucagon‐like
peptide‐1
receptor
agonists
(GLP‐1RAs)
have
emerged
as
first‐line
treatments
for
T2D
based
on
significant
weight
loss
results.
The
composition
using
most
diets
consists
<25%
fat‐free
mass
(FFM)
loss,
with
remainder
from
fat
stores.
Higher
amounts
(achieved
metabolic
bariatric
surgery)
result
in
greater
reductions
FFM.
Our
aim
was
to
assess
impact
that
GLP‐1RA‐based
We
analysed
studies
reported
changes
FFM
following
agents:
exenatide,
liraglutide,
semaglutide,
and
dual
incretin
agonist
tirzepatide.
performed
an
analysis
various
interventions
provide
a
reference
expected
evaluated
dual‐energy
X‐ray
absorptiometry
(DXA)
measuring
(a
crude
surrogate
skeletal
muscle).
In
evaluating
percentage
lost
(%FFML)
equal
ΔFFM/total
change.
%FFML
agents
between
20%
40%.
28
clinical
trials
evaluated,
proportion
highly
variable,
but
majority
exceeding
25%.
review
limited
small
substudies
use
DXA,
which
does
not
measure
muscle
directly.
Since
contains
variable
amount
(approximately
55%),
this
indirect
may
explain
heterogeneity
data.
Assessing
quantity
quality
advanced
imaging
(magnetic
resonance
imaging)
functional
testing
will
help
fill
gaps
our
current
understanding.
Language: Английский
Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes
Diabetes Obesity and Metabolism,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 11, 2025
Abstract
Obesity
and
type
2
diabetes
mellitus
(T2D)
are
widespread
diseases
that
significantly
impact
cardiovascular
renal
morbidity
mortality.
In
the
recent
years,
intensive
research
has
been
performed
to
assess
role
of
adipose
tissue
body
fat
distribution
in
development
metabolic
non‐metabolic
complications
individuals
with
obesity.
addition
lifestyle
modifications,
glucagon‐like
peptide‐1
receptor
agonists
(GLP‐1‐RA)
have
become
a
meaningful
treatment
expansion
for
management
both
disorders.
improving
control
reducing
weight,
GLP‐1‐RAs
reduces
events
obesity
without
diabetes.
These
important
benefits
triggered
new
interest
other
enteroendocrine
enteropancreatic
peptides
treating
its
consequences.
The
first
peptide
dual‐agonist
targeting
glucose‐dependent
insulinotropic
polypeptide
(GIP)
GLP‐1
receptors
approved
T2D
GIP/GLP‐1
dual‐agonism
appear
provide
better
greater
weight
reduction
compared
GLP‐1‐R
mono‐agonism.
Other
non‐peptide
co‐agonists
clinical
obesity,
T2D,
dysfunction‐associated
steatotic
liver
disease
(MASLD)
This
narrative
review
aims
summarize
available
data
on
emerging
based
approaches
efficacy
measures,
side
effects,
limitations
open
challenges
will
also
be
addressed.
Language: Английский